US 12,275,795 B2
Binding molecules against BCMA and uses thereof
Aida Abujoub, Winchester, MA (US); John Blankenship, Acton, MA (US); Tony Fleming, Stow, MA (US); Brian Holmberg, Somerville, MA (US); Connie Hong, Somerville, MA (US); Lu Huang, Cambridge, MA (US); and Haihui Lu, Cambridge, MA (US)
Assigned to NOVARTIS AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Sep. 21, 2022, as Appl. No. 17/934,064.
Application 17/934,064 is a division of application No. 16/426,914, filed on May 30, 2019, granted, now 11,492,409.
Claims priority of provisional application 62/679,611, filed on Jun. 1, 2018.
Claims priority of provisional application 62/684,046, filed on Jun. 12, 2018.
Prior Publication US 2023/0295322 A1, Sep. 21, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 14/735 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/283 (2013.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C07K 16/468 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01)] 23 Claims
 
1. A nucleic acid or plurality of nucleic acids encoding a B-cell maturation antigen (BCMA) binding molecule that specifically binds to human BCMA and comprises:
(a) according to the combined Kabat and Chothia definitions a CDR-L1, CDR-L2 and CDR-L3 sequence of SEQ ID NOs: 26, 102, and 110, respectively, and a CDR-H1, CDR-H2 and CDR-H3 sequence of SEQ ID NOs: 188, 112, and 49, respectively;
(b) according to the Kabat definition a CDR-L1, CDR-L2 and CDR-L3 sequence of SEQ ID NOs: 26, 102, and 110, respectively, and a CDR-H1, CDR-H2 and CDR-H3 sequence of SEQ ID NOs: 39, 112, and 49, respectively;
(c) according to the Chothia definition a CDR-L1, CDR-L2 and CDR-L3 sequence of SEQ ID NO: 27, DVS, and SEQ ID NO: 136, respectively, and a CDR-H1, CDR-H2 and CDR-H3 sequence of SEQ ID NOs: 138, 140, and 49, respectively; or
(d) according to the IMGT definition a CDR-L1, CDR-L2 and CDR-L3 sequence of SEQ ID NOs: 28, 154, and 110, respectively, and a CDR-H1, CDR-H2 and CDR-H3 sequence of SEQ ID NOs: 162, 165, and 51, respectively.